Aaron Diamond AIDS Research Center

Last updated

Aaron Diamond AIDS Research Center, often abbreviated as ADARC, is a medical research institution dedicated to finding a cure for HIV/AIDS. It is headed by scientist Dr. David Ho, who was the 1996 Time magazine Person of the Year, and is located in New York City. [1]

Opening in 1991, the center was the brainchild of the Aaron Diamond Foundation headed by his widow Irene Diamond, the New York City Department of Health, the Public Health Research Institute and New York University School of Medicine. It became affiliated with Rockefeller University in 1996, and became part of Columbia University's medical school, Columbia University Vagelos College of Physicians and Surgeons, in 2019. [2] [3]

One is the introduction of combination antiretroviral therapy [4] to combat HIV drug resistance [4] [5] and hence prevent [6] progression to fatal full-blown AIDS. David Ho and his team presented their remarkable clinical trial results at the International AIDS Conference 1996. [7] This marked a turning point in which HIV infection was no longer an absolute terminal disease but a manageable chronic disease. [8]

Related Research Articles

<span class="mw-page-title-main">David Ho</span> Asian-American physician and scientist

David Da-i Ho is a Taiwanese American AIDS researcher, physician, and virologist who has made a number of scientific contributions to the understanding and treatment of HIV infection. He championed for combination anti-retroviral therapy instead of single therapy, which turned HIV from absolute terminal disease into a chronic disease.

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

<span class="mw-page-title-main">Stavudine</span> Chemical compound

Stavudine (d4T), sold under the brand name Zerit among others, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretrovirals. It may be used for prevention after a needlestick injury or other potential exposure. However, it is not a first-line treatment. It is given by mouth.

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

<span class="mw-page-title-main">Abacavir</span> Chemical compound

Abacavir, sold under the brand name Ziagen among others, is a medication used to treat HIV/AIDS. Similar to other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is used together with other HIV medications, and is not recommended by itself. It is taken by mouth as a tablet or solution and may be used in children over the age of three months.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

This is a timeline of HIV/AIDS, including cases before 1980.

<span class="mw-page-title-main">Robert Yarchoan</span>

Robert Yarchoan is a medical researcher who played an important role in the development of the first effective drugs for AIDS. He is the Chief of the HIV and AIDS Malignancy Branch in the NCI and also coordinates HIV/AIDS malignancy research throughout the NCI as director of the Office of HIV and AIDS Malignancy (OHAM).

<span class="mw-page-title-main">Lamivudine/zidovudine</span> Combination drug for HIV

Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.

Douglas D. Richman is an American infectious diseases physician and medical virologist. Richman's work has focused on the HIV/AIDS pandemic, since its appearance in the early 1980s. His major contributions have been in the areas of treatment, drug resistance, and pathogenicity.

<span class="mw-page-title-main">Joep Lange</span> Dutch clinical researcher (1954–2014)

Joseph Marie Albert "Joep" Lange was a Dutch clinical researcher specialising in HIV therapy. He served as the president of the International AIDS Society from 2002 to 2004. He was a passenger on Malaysia Airlines Flight 17, which was shot down on 17 July 2014 over Ukraine.

The history of HIV/AIDS in Australia is distinctive, as Australian government bodies recognised and responded to the AIDS pandemic relatively swiftly, with the implementation of effective disease prevention and public health programs, such as needle and syringe programs (NSPs). As a result, despite significant numbers of at-risk group members contracting the virus in the early period following its discovery, Australia achieved and has maintained a low rate of HIV infection in comparison to the rest of the world.

<span class="mw-page-title-main">HIV disease–related drug reaction</span>

HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.

Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors began in the 1980s when the AIDS epidemic hit Western societies. NRTIs inhibit the reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of the human immunodeficiency virus (HIV). The first NRTI was zidovudine, approved by the U.S. Food and Drug Administration (FDA) in 1987, which was the first step towards treatment of HIV. Six NRTI agents and one NtRTI have followed. The NRTIs and the NtRTI are analogues of endogenous 2´-deoxy-nucleoside and nucleotide. Drug-resistant viruses are an inevitable consequence of prolonged exposure of HIV-1 to anti-HIV drugs.

The XI International AIDS Conference was held in Vancouver July 7–12, 1996. The theme of the conference was "One World One Hope".

Julio S. G. Montaner, is an Argentine-Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

References

  1. ↑ Park, Alice (25 January 2010). "Scientist David Ho: The Man Who Could Beat AIDS". Time. Archived from the original on June 4, 2011. Retrieved 24 January 2010.
  2. ↑ "Aaron Diamond AIDS Research Center to Join Columbia University". 19 March 2019. Archived from the original on 7 June 2023.
  3. ↑ "Aaron Diamond AIDS Research Center will end 23-year affiliation with Rockefeller". 2019-03-20. Archived from the original on 2022-12-08.
  4. 1 2 Ho, David (August 17, 1995). "Time to Hit HIV, Early and Hard" . New England Journal of Medicine . 333 (7): 450–451. doi:10.1056/NEJM199508173330710. PMID   7616996. Archived from the original on September 1, 2015. Retrieved January 29, 2023. ... zidovudine was shown in 1990 to slow the clinical progression to AIDS in infected but asymptomatic subjects. However, a follow-up of those subjects found no evidence of longer survival with the use of zidovudine...
  5. ↑
  6. ↑
    • "Interviews - David Ho - The Age Of Aids - Frontline". Frontline. PBS. May 30, 2006. Archived from the original on March 7, 2007. Retrieved January 29, 2023. ... if you start to combine the drugs and try to force the virus into a corner using multiple drugs, it is exceedingly difficult or statistically improbable for HIV to become resistant to all the drugs simultaneously.
    • "The Age of AIDS, Part II". Frontline . Season 24 (2006). Episode 11. 2006-05-31. Event occurs at 0:18:54. PBS . Retrieved 2023-01-31. ... However, if you start to combine the drugs and try to force the virus into a corner using multiple drugs, it is exceedingly difficult...for HIV to become resistant to all the drugs simultaneously. 
  7. ↑ "The Age of AIDS, Part II". Frontline . Season 24 (2006). Episode 11. 2006-05-31. Event occurs at 0:21:50. PBS . Retrieved 2023-01-31. International AIDS Conference 1996 in Vancouver showing combination therapy results
  8. ↑ Mahungu, Tabitha; Rodger, Alison; Johnson, Margaret (2009-04-01). "HIV as a chronic disease". Clinical Medicine . 9 (2): 125–128. doi:10.7861/clinmedicine.9-2-125. PMC   4952661 . PMID   19435115. Archived from the original on 2020-07-23. Retrieved 2023-01-31.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.